Topic: Mcam

Dr. David Martin and his company MCAM monitored global biological and chemical weapons labs through patent filings and grants starting in 1998. Pfizer filed the first coronavirus vaccine patent in 1990, followed by Ralph Baric's 2001 research into modifying the virus to target heart tissue. Documents from 2014 and 2016 indicate that NIAID and Anthony Fauci were aware of gain-of-function studies at the University of North Carolina Chapel Hill involving the WIV-1 virus.

Dr. David E. Martin, chairman of MCAM Inc., visited Austin, Texas, for an emergency meeting with the state legislature regarding criminal charges related to COVID-19. Martin has spent years monitoring biological weapons and was among the first to analyze the genetic code of the virus in early 2020. The discussion focuses on the willful misleading of the global population through coerced medical interventions.

Mosaic Technologies was founded in the 1990s to civilianize offensive military technologies for export under ITAR rules. This work led to the creation of MCAM, which monitors 68 scheduled pathogens in the global biological weapons arsenal for the U.S. Commerce and Treasury Departments. Surveillance intensified following the 2001 anthrax attacks, which originated from a U.S. lab at Fort Detrick.